Prognia
Drug Database
🇪🇺EU · EMAWithdrawn

Eurifel RCP FeLV(canarypox virus expressing feline leukemia virus, live;feline calicivirus, strain 255, inactivated;feline panleucopenia virus, strain PLI IV, live;feline rhinotracheitis virus, strain C27, antigen)

Marketing Authorisation Holder: Merial

EMA Authorisation: 08/03/2002

INN: vaccine against feline viral rhinotracheitis, calicivirosis, panleucopenia and leukaemia in cats

Indication

Vaccine against feline viral rhinotracheitis, feline calicivirosis, feline panleucopenia and feline leukaemia. Stimulates active immunity against feline rhinotracheitis virus, feline calicivirus, feline panleucopenia virus and feline leukaemia virus. The feline leukaemia vaccine strain is a recombinant canarypox virus expressing the env and gag genes of FeLV-A. Under field conditions, only sub-group A is infective and immunisation against subgroup A provides full protection against A, B and C. After inoculation, the virus expresses the protective proteins, but does not replicate in the cat. As a consequence, the vaccine induces an immune status against feline leukaemia virus.

Official EMA Resources

View on EMA (ema.europa.eu)

AI Drug & Interaction Analysis

Free account required

Ask Prognia AI about Eurifel RCP FeLV — dosing recommendations, drug interactions, and current guideline evidence from ESC, EMA, NICE and more.

Medical disclaimer: This information is intended for qualified healthcare professionals. Always verify with the official EMA Summary of Product Characteristics (SmPC) before clinical use.